Strategies to target TXNIP and osteopontin are being developed and such approaches could be appraised alone or in combination with other therapies in canine HS [6, 22], thus paving the way to improve treatment of human HS, which remains a deadly disease. This evidence concerns the gene TXNIP and histiocytic sarcoma.